Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. prevent

PREVENT

Prostate cancer extracellular vesicles as biomarkers for nanomedicine treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 PREVENT project word cloud

Explore the words cloud of the PREVENT project. It provides you a very rough idea of what is the project "PREVENT" about.

cytotoxic    fluids    communication    worldwide    extracellular    fingerprint    prognosis    efficacy    nanomedicine    guided    platforms    sirnas    prevent    antigen    excitement    biomarker    loaded    evs    biopsies    composition    lethal    treatment    evaluation    tumour    survival    exploited    therapy    containing    urine    free    samples    detected    curable    candidates    strategy    therapies    cdx    vesicles    companion    monitor    cytometry    cancer    prostate    intercellular    genes    types    patients    synergistic    immunocapture    immunodetection    standard    therapeutic    employ    castration    ing    ultimately    nanomedicines    patient    resistant    bodily    cell    cells    altered    released    blood    males    crpc    preclinical    lipid    invasive    levels    diagnosis    lnps    clinical    combination    liquid    created    agent    rational    plasma    reduce    pc    psa    disease    parental    microfluidics    diagnostic    anti    drug    nanoparticles    predictability    deadliest    docetaxel    stage    prepared    flow    collect    co   

Project "PREVENT" data sheet

The following table provides information about the project.

Coordinator		 UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

Organization address
address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX
website: www.umcutrecht.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Netherlands [NL]
 Total cost 228˙421 €
 EC max contribution 228˙421 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-GF
 Starting year 2015
 Duration (year-month-day) from 2015-09-14   to  2018-09-13

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) coordinator 228˙421.00
2    UNIVERSITY OF BRITISH COLUMBIA CA (VANCOUVER) partner 0.00

Map

 Project objective

Prostate cancer (PC) is one of the deadliest types of cancer in males worldwide. Early stage PC is often curable but many patients develop castration-resistant prostate cancer (CRPC), resulting in lethal end-stage disease. Prostate specific antigen (PSA) plasma levels have been traditionally exploited for diagnosis and prognosis. However, the application of PSA as a biomarker is associated with predictability issues. Advanced therapies are required for the treatment of CRPC, guided by a reliable companion diagnostic (CDx) test to monitor therapeutic efficacy. The aim of “PREVENT” is to co-develop a nanomedicine-based combination therapy for the treatment of CRPC and a CDx based on extracellular vesicles (EVs). I will employ tumour-targeted nanomedicines to deliver more drug to the tumour and reduce side effects when compared to free drug. The treatment comprises microfluidics-prepared lipid nanoparticles (LNPs) containing siRNAs that target genes involved in CRPC and LNPs loaded with the cytotoxic anti-cancer agent docetaxel to achieve synergistic therapeutic effects. For the CDx test, extracellular vesicles (EVs) have created excitement as possible biomarker candidates. EVs are released by cells as means of intercellular communication and can be detected in bodily fluids. The number of EVs and their composition is altered in CRPC, raising opportunities to exploit them in a CDx test. As EVs provide a fingerprint of their parental cell, EVs can be considered liquid biopsies, providing more information than standard biomarker measurements, and much less invasive than prostate biopsies. I will collect blood and urine samples during the preclinical evaluation of the proposed treatment for analysis using immunocapture and flow cytometry-based immunodetection platforms. The co-development of a nanomedicine combination treatment for CRPC and a CDx test is a rational strategy that has the potential to advance into clinical evaluation and ultimately improve patient survival.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREVENT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PREVENT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

GrowthDevStability (2020)

Characterization of the developmental mechanisms ensuring a robust symmetrical growth in the bilateral model organism Drosophila melanogaster

Read More  

RegulatioNFkB (2019)

Deciphering transcriptional regulation of NF-kB target genes using integrative omics approaches

Read More